Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nexus Surgical and Medicare's annualized ROCE % for the quarter that ended in Mar. 2026 was 65.90%.
Nexus Surgical and Medicare (BOM:538874) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Nexus Surgical and Medicare ROCE % Related Terms
Nexus Surgical and Medicare ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexus Surgical and Medicare (BOM:538874) has a ROCE % of 65.90% as of Mar. 2026.
Is Nexus Surgical and Medicare's ROCE % too high?
Nexus Surgical and Medicare's current ROCE % is 65.90%. The Medical Distribution industry median ROCE % is 8.92. Nexus Surgical and Medicare's value of 65.90% is 638.8% above this industry median. Overall, Nexus Surgical and Medicare has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nexus Surgical and Medicare's ROCE % compare to MCK and CAH?
Nexus Surgical and Medicare's ROCE % of 65.90% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. Nexus Surgical and Medicare's value of 65.90% is 638.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexus Surgical and Medicare's current ROCE % of 65.90% is 638.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexus Surgical and Medicare's current ROCE % is 65.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexus Surgical and Medicare stock overvalued right now?
Based on GuruFocus' analysis, Nexus Surgical and Medicare (BOM:538874) is currently considered Possible Value Trap. The stock's GF Value™ is ₹33.71, compared to a current price of ₹19.15 — trading 43.2% below its estimated fair value. The current ROCE % is 65.90% and 638.8% above the Medical Distribution industry median of 8.92. Nexus Surgical and Medicare's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Nexus Surgical and Medicare (BOM:538874), the current ROCE % is 65.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexus Surgical and Medicare (BOM:538874) Overvalued in 2026?
Based on GuruFocus' analysis, Nexus Surgical and Medicare stock appears to be undervalued.
The current stock price of ₹19.15 is trading 43.2% below its estimated GF Value™ of ₹33.71.
GuruFocus considers Nexus Surgical and Medicare to be Possible Value Trap.
Key valuation signals for BOM:538874:
ROCE %: 65.90%
GF Value™: ₹33.71 vs. price of ₹19.15 (43.2% below fair value)
Industry Position: 638.8% above the Medical Distribution median
No single metric tells the full story. See the BOM:538874 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexus Surgical and Medicare Ltd is involved in Importing and Marketing Quality Surgical and Pharmaceutical Products at an Economical Price. The Company is a wholesale dealer dealing in various sizes of disposal syringes (with and without needles) and pouches of various sizes used for the storage of sterilized equipment and materials. It operates in the segment of trading activities.
82GF Score
Get the complete analysis for BOM:538874
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538874 has been successfully added to your 
